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Summary
 
Anti-CD3 monoclonal antibodies (mAbs) are potent immunosuppressive agents used in clinical
transplantation. However, the activation-related adverse side effects associated with these mAbs
have prompted the development of less toxic nonmitogenic anti-CD3 mAb therapies. At present,
the functional and biochemical consequences of T cell exposure to nonmitogenic anti-CD3 is
unclear. In this study, we have examined the early signaling events triggered by a nonmitogenic
anti-CD3 mAb. Like the mitogenic anti-CD3 mAb, nonmitogenic anti-CD3 triggered changes
in the T cell receptor (TCR) complex, including 
 
z
 
 chain tyrosine phosphorylation and ZAP-70
association. However, unlike the mitogenic anti-CD3 stimulation, nonmitogenic anti-CD3 was
ineffective at inducing the highly phosphorylated form of 
 
z
 
 (p23) and tyrosine phosphorylation
of the associated ZAP-70 tyrosine kinase. This proximal signaling deficiency correlated with
minimal phospholipase C
 
g
 
-1 phosphorylation and failure to mobilize detectable Ca
 
2
 
1
 
. Not
only did biochemical signals delivered by nonmitogenic anti-CD3 resemble altered peptide
ligand signaling, but exposure of Th1 clones to nonmitogenic anti-CD3 also resulted in func-
tional anergy. Finally, a bispecific anti-CD3 
 
3
 
 anti-CD4 F(ab)
 
9
 
2
 
 reconstituted early signal
transduction events and induced proliferation, suggesting that defective association of lck with
the TCR complex may underlie the observed signaling differences between the mitogenic and
nonmitogenic anti-CD3.
 
O
 
KT3, a murine antibody specific for the CD3
 
e
 
 chain
of the TCR complex, has been used clinically for
over a decade in the treatment of steroid-resistant graft re-
jection (1). However, use of this antibody has been ham-
pered by a toxic first dose reaction syndrome shown to be
related to the initial T cell activation events and ensuing re-
lease of cytokines before the suppression of T cell responses
(2, 3). Others have demonstrated that the mitogenic activ-
ity of OKT3 and other anti-CD3 mAbs depends upon ex-
tensive TCR–CD3 cross-linking via binding to FcR-posi-
tive cells (4). Therefore, recent efforts have been devoted
to developing nonmitogenic forms of anti-CD3 by altering
binding to Fc receptor. As a model system, an anti-murine
CD3 mAb, 145-2C11, was genetically altered to eliminate
FcR binding: its variable region gene was fused to a murine
IgG3 Fc region, a mouse isotype with low affinity for mu-
rine FcR. This chimeric anti-CD3–IgG3 antibody has
been shown to be nonmitogenic in vitro, and did not result
in the serum cytokine elevation observed with the whole
145-2C11 mAb in vivo (5). However, the administration
of nonmitogenic anti-CD3 mAbs was equally effective in
prolonging graft survival as the parental 145-2C11 anti-
body (5). As similar non-FcR-binding mAbs derived from
OKT3 are being tested clinically, it is important to gain
further understanding of the mechanism(s) by which these
nonmitogenic mAbs suppress T cell responses.
The mechanism of immunosuppression by anti-CD3
mAbs is complex. Mitogenic anti-CD3 mAbs modulate the
TCR, induce apoptosis, and induce generalized long-term
T cell unresponsiveness (6). Similarly, treatment of mice
with the nonmitogenic anti-CD3 results in internalization
of the TCR complex and depletion of T cells from the cir-
culation and peripheral lymphoid organs. However, in
contrast with the mitogenic antibodies, anti-CD3–IgG3 does
not appear to induce global T cell unresponsiveness (5). Thus,
the different anti-CD3 mAbs may suppress T cell responses
by distinct mechanisms. Treatment with anti-CD3–IgG3
alters expression of several T cell surface molecules; both
CD44 and Ly-6C are upregulated after exposure to the chi-
meric anti-CD3 (7). Thus, the interaction of anti-CD3–
IgG3 with T cells is not inert, but may deliver at least a
partial TCR signal that contributes to its immunosuppres-
sive activity.
Currently, it is thought that TCR signaling results from
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a cascade of events requiring the recruitment and activation
of nonreceptor tyrosine kinases. One of the earliest conse-
quences of TCR engagement by mAb or peptide–MHC is
the tyrosine phosphorylation of components of the TCR
complex (8). The 
 
z
 
 chain of the TCR complex contains
three immunoreceptor tyrosine-based activation motifs (D/
EXXYXXL(X)
 
6–8
 
 YXXL) that become variably phosphory-
lated after TCR–CD3 ligation (9). It is thought that the
activation-induced 21- and 23-kD phosphorylated bands
evident on one-dimensional SDS-PAGE represent differ-
entially phosphorylated forms of 
 
z
 
 (10). The other CD3
chains, 
 
g
 
, 
 
d
 
, and 
 
e
 
 (containing one immunoreceptor tyrosine-
based activation motif each), become tyrosine phosphory-
lated as well (8). It has been hypothesized that the src fam-
ily kinases, lck or fyn, may be responsible for these early
phosphorylation events (9). Within minutes, additional ty-
rosine phosphorylated proteins, including the ZAP-70
kinase, associate with the TCR–CD3 complex (11). These
proximal events lead to a series of biochemical signals that
activate downstream substrates in the PI-3 kinase, Ras, and
phospholipase C
 
g
 
-1 (PLC
 
g
 
-1)
 
1
 
 pathways, ultimately lead-
ing to activation of the T cell (9).
Until recently, it was thought that this cascade of events
was always fully engaged after exposure to peptide–MHC
ligand or mAbs and that different responses to stimuli re-
flected a quantitative addition of the number of receptors
engaged. However, antigenic peptide analogues, designated
as altered peptide ligands (APL), have illustrated that the
TCR is not an on–off switch. Rather, stimulation with
APL can result in qualitative differences in the early signals
transduced through the TCR. Specifically, stimulation with
APL results in a characteristic biochemical pattern involv-
ing partial 
 
z
 
 phosphorylation and ZAP-70 association in
the absence of phosphorylation, ultimately leading to a lack
of inositol–trisphosphate (IP
 
3
 
) turnover (10, 12, 13). The
delivery of such a partial signal effectively shuts down T cell
clones, resulting in the induction of unresponsiveness as
manifested by an inability of the anergized T cell clones to
produce IL-2 when rechallenged under optimal conditions.
In the present study, we examined the effect of nonmi-
togenic anti-CD3 mAbs on early signaling events in T cell
clones. The anti-CD3–IgG3 chimeric antibody transduced
a signal characterized by an altered pattern of 
 
z
 
 chain and
ZAP-70 tyrosine phosphorylation, leading to defects in
downstream signaling events. Nonmitogenic anti-CD3 also
failed to induce higher order aggregation of the TCR into
a cap. Similar signaling changes were observed in naive T
cells at the level of TCR complex and PLC
 
g
 
-1 tyrosine
phosphorylation. Specific defects in early signal transduc-
tion and mitogenicity were restored by coaggregating CD4
(and thus presumably lck) with the TCR–CD3 complex. The
nonmitogenic anti-CD3 induced T cell unresponsiveness
in Th1 clones but not naive T cells. Together, these results
suggest that administration of nonmitogenic anti-CD3 mAbs,
especially in recipients undergoing acute transplant rejec-
tion, may result in the delivery of a partial T cell signal that
renders activated T cells unresponsive.
 
Materials and Methods
 
Animals.
 
6- to 8-wk-old BALB/c, DBA/2J, and B10.A mice
were purchased from Frederick Cancer Research Institute Labo-
ratories (Frederick, MD). DO 11.10 mice, transgenic for an OVA
peptide (323–339)-specific, I-A
 
d
 
–restricted 
 
ab
 
-TCR, were a gift
of Drs. D. Loh and K. Murphy (Washington University, St.
Louis, MO) (14). All mice were bred and maintained in a specific
pathogen-free facility at the University of Chicago.
 
Cell Lines, Antibodies, and Reagents.
 
The chicken OVA-spe-
cific Th1 clone pGL10 was provided by Dr. F. Fitch (University of
Chicago, Chicago, IL) and the pigeon cytochrome c (PCC)–specific
Th1 clone, AE.7, was provided by Dr. M. Jenkins (University of
Minnesota, Minneapolis, MN). OVA and PCC were purchased
from Sigma Chem. Co. (St. Louis, MO). The following mAbs were
used in this study: 145-2C11 (anti-CD3), AT83A (anti-Thy-1)
(provided by Dr. F. Fitch, University of Chicago, Chicago, IL);
anti-CD3–IgG3 (5, 7); the anti-Ig antisera: goat anti–mouse IgG3
(Sigma), rabbit anti–mouse IgG3 (Zymed, San Francisco, CA),
rabbit anti–hamster (Cappel, Durham, NC); 145-2C11–FITC
(Boehringer Mannheim, Indianapolis, Indiana); PV-1 (anti-CD28)
(Dr. C. June, Naval Medical Research Institute, MD); H146
(anti-
 
z
 
 mAb containing supernatant) (Dr. F. Fitch); 4G10 (anti-
phosphotyrosine) and anti-PLC
 
g
 
-1 (mixed mAbs) (UBI, Lake
Placid, NY); 12-222 (anti-ZAP-70 antiserum) (Dr. A. Weiss,
University of California, San Francisco, CA). Cyclosporine A was
purchased from Sandoz (Basel, Switzerland). Indo-1 was pur-
chased from Molecular Probes (Eugene, OR).
 
Anti-CD3–Fos 
 
3
 
 Anti-CD4–Jun Bispecific F(ab
 
9
 
–Zipper)
 
2
 
 Pro-
duction.
 
The anti-CD3 antibody was derived from hamster anti–
mouse CD3 hybridoma 145-2C11 (15), and the anti-CD4 anti-
body from rat anti–mouse CD4 hybridoma GK1.5 (16). The VH
and VL sequences for 145-2C11 (5), (GenBank accession no.
U17870 and U17871) and GK1.5 (16, 16a) had been determined.
Homodimers of anti-CD3–Fos and anti-CD4–Jun F(ab
 
9
 
–zipper)
 
2
 
were expressed by the genetic method described by Kostelny et
al., (17). Anti-CD3–Fos and anti-CD4–Jun were individually pu-
rified from transfected Sp2/0 spent media by protein G–Sepharose
affinity chromatography (18). The two homodimers were then re-
duced and reoxidized to form bispecific F(ab
 
9
 
–zipper)
 
2
 
 as de-
scribed (17). Bispecific F(ab
 
9
 
–zipper)
 
2
 
 was further purified by
BAKERBOND Abx column chromatography or hydrophobic in-
teraction chromatography on a Bio-Gel
 
Ò
 
 Phenyl-5 PW column.
 
Proliferation Assays.
 
pGL10 and AE.7 T cell clones were main-
tained as previously described (19, 20). T cell clones were purified
by Ficoll–HyPaque density centrifugation before use in all exper-
iments. BALB/c spleens were lysed in hypotonic ACK buffer to
remove erythrocytes. Proliferation and unresponsiveness assays
were in 5 or 10% FCS supplemented DMEM. In a 96-well flat-bot-
tomed plate, 2 
 
3
 
 10
 
5
 
 splenocytes or 1 
 
3
 
 10
 
5
 
 pGL10 T cells were
incubated on ice for 10 min with anti-CD3 (final concentration
of 1 
 
m
 
g/ml), and then for another 10 min on ice with the appro-
priate cross-linker (rabbit anti–IgG3 at 1:30 or goat anti–IgG3 at
1:100 or goat anti–hamster at 1:300), before being placed at 37
 
8
 
C.
For anti-CD3–Fos homodimer or anti-CD3 
 
3
 
 anti-CD4 het-
erodimer proliferation assays, antibodies were serially diluted in
96-well flat-bottomed plates, starting at 10 
 
m
 
g/ml. Assays were
pulsed with 1 
 
m
 
Ci/well of [
 
3
 
H]thymidine for the last 8 h of a 48-h
incubation, harvested on a Filtermate 196 96-well plate harvester
 
1
 
Abbreviations used in this paper:
 
 APL, altered peptide ligands; IP
 
3
 
, inositol–
triphosphate; PCC, pigeon cytochrome C; PLC
 
g
 
-1, phospholipase C
 
g
 
-1.
 1415
 
Smith et al.
(Packard Instrument Co., Meriden, CT), and counted on a Pack-
ard TopCount microplate scintillation counter. Results are pre-
sented as the mean of triplicate cultures. Standard errors were less
than 20% of the mean.
For induction of unresponsiveness, 24-well plates were pre-
blocked with 10% FCS-supplemented DMEM overnight to pre-
vent soluble anti-CD3–IgG3 from adhering to the plastic. DO
11.10 lymph node cells (2 
 
3
 
 10
 
6
 
) or pGL10 clones (1 
 
3
 
 10
 
6
 
)
were incubated 24 h in 1 ml media with or without 1–10 
 
m
 
g/ml
soluble anti-CD3–IgG3, CsA (1 
 
m
 
g/ml), anti-CD28 (1 
 
m
 
g/ml),
2–3 
 
3
 
 10
 
6
 
 T-depleted irradiated BALB/c splenocytes. Cells were
then washed three times, and rested 72 h at 37
 
8
 
C. TCR reexpres-
sion was verified via FACS
 
Ò
 
 analysis. For the secondary stimula-
tion, 4–5 
 
3
 
 10
 
4
 
 DO 11.10 lymph node cells or pGL10 cells were
plated in the presence of 2–5 
 
3
 
 10
 
5
 
 T-depleted (anti-Thy-1 plus
complement) irradiated splenocytes and 1 
 
m
 
g/ml soluble 145-2C11
or 800 
 
m
 
g/ml OVA. Cultures were pulsed with [
 
3
 
H]thymidine af-
ter 48 h. For IL-2 production, 2.5 
 
3
 
 10
 
4
 
 cells per well were stim-
ulated in a 96-well flat-bottomed plate with immobilized anti-
CD3 plus anti-CD28 at 1 
 
m
 
g/ml. 24 h supernatants from 3 wells
were pooled and analyzed by ELISA (Endogen, Cambridge,
MA). For AE.7 assays, 1 
 
3
 
 10
 
6
 
 T cells per well were incubated
for 24 h with 1 
 
m
 
g/ml of anti-CD3–IgG3 mAb, washed, rested,
and then in a 96-well flat bottomed plate, 4 
 
3
 
 10
 
4
 
 T cells were
restimulated in the presence of 5 
 
3
 
 10
 
5
 
 T-depleted irradiated
B10.A splenocytes and 10 
 
m
 
M PCC.
 
Biochemistry.
 
T cell clones or BALB/c lymph node cells were
washed in PBS and then resuspended in ice-cold PBS at 1 
 
3
 
 10
 
8
 
/ml
or 2 
 
3
 
 10
 
8
 
/ml, respectively. Anti-CD3–IgG3 was added at 4–5
 
m
 
g/ml for a 10-min incubation on ice. An equal volume of anti-
Ig cross-linker or PBS prewarmed to 37
 
8
 
C was added and samples
were incubated a further 2.5–5 min in a 37
 
8
 
C water bath. For
anti-CD3–Fos homodimer and anti-CD3 
 
3
 
 anti-CD4 heterodimer
stimulations, cells were stimulated with 10 
 
m
 
g/ml of antibody. Af-
ter the incubation, an equal volume of ice-cold 2
 
3
 
 lysis buffer
was added (final concentration: 0.5% Triton X-100, 50 mM Tris
[pH7.6], 100 mM NaCl, 5 mM EDTA, 1 mM Na
 
3
 
VO
 
4
 
, 10 
 
m
 
g/
ml each leupeptin and aprotonin, 25 
 
m
 
M NPGB, and 1 mM
PMSF). For immunoprecipitations, 20 
 
l
 
 of a 50% protein A–aga-
rose bead slurry (Pharmacia-UpJohn, Uppsala, Sweden) were
coated with 200 
 
l
 
 of mAb-containing supernatant or 2 
 
l
 
 of anti-
sera for 1 h at 4
 
8
 
C. Lysates were added to the precoated protein
A–agarose beads and incubated 1 h at 4
 
8
 
C. The samples were re-
solved on a 12% SDS–polyacrylamide gel for 
 
z
 
 immunoprecipita-
tions or an 8% gel for PLC
 
g
 
-1, and then transferred to PVDF
membrane (Millipore, Bedford, MA). Blots were blocked with
10% BSA (Sigma, St. Louis, MO). After incubation with primary
antibody and the appropriate horseradish–peroxidase-coupled sec-
ondary antibody, blots were developed by Enhanced Chemilumi-
nescence (Amersham Corp., Arlington Heights, IL). Densitometry
measurements were performed using an AMBIS Image Acquisi-
tion and Analysis instrument (San Diego, CA).
 
Calcium Flux.
 
pGL10 were washed with DMEM containing
10 mM Hepes at pH 7.0 and then incubated at 5 
 
3 106 cells/ml
with 5 mM indo-1 at 378C for 30 min. An equal volume of DMEM
with Hepes and 5% FCS at pH 7.4 was added and cells were in-
cubated 30 min. Cells were washed twice with 5% FCS-supple-
mented DMEM at pH 7.2 and resuspended at 1 3 106/ml for
data acquisition on a FACStarÒ  plus (Becton Dickenson Immu-
nocytometry Systems, Mountain View, CA). Cells were briefly
warmed before stimulation with anti-CD3–IgG3 (1 mg/ml) plus
rabbit anti–IgG3 (1:30). An increase in the 404:495 nm indo-1
emission ratio is indicative of a rise in intracellular Ca21. Results
were analyzed using Multitime (Phoenix Flow Systems, San Di-
ego, CA).
Confocal Microscopy. Purified DO 11.10 lymph node T cells
or pGL10 cells (106) were incubated with 5 mg/ml 145-2C11–
FITC on ice for 10 min and then stimulated with an equal vol-
ume of 378C prewarmed goat anti–hamster in PBS (1:300 final)
for 0 or 5 min at 378C. T cells were transferred to a polystyrene
FACS Ò  tube and fixed in 3% paraformaldehyde for 10 min at
room temperature, washed three times with PBS, and then resus-
pended in 25 l of mounting solution (0.5 mg/ml O-Phenylene-
diamine, 90% glycerol, 0.05 M Tris [pH 8.0], 0.2% NaN3). Sam-
ples were analyzed on a ZEISS 410 confocal microscope.
Results
The anti-CD3–IgG3 mAb Is Nonmitogenic Due to Insuffi-
cient Cross-linking of the TCR. Unlike the original 145-2C11
mAb, the anti-CD3–IgG3 chimeric antibody does not in-
duce proliferation or IL-2 production in whole spleen cells
(5). Also, soluble 145-2C11 failed to induce proliferation of
T cell clones in the absence of FcR-mediated cross-linking
(Bluestone, J.A. and J.A. Smith, unpublished observations;
data not shown). To test directly the role of multivalent cross-
linking, a secondary IgG3-specific cross-linking antibody
was added to cultures containing the anti-CD3–IgG3 mAb.
The addition of the cross-linking reagent reconstituted a
mitogenic stimulus for both fresh murine splenocytes and a
T cell clone (Fig. 1). Thus, the induction of proliferation
by anti-CD3 requires a higher order of TCR aggregation
that cannot be achieved by bivalent Ab binding alone.
Nonmitogenic Anti-CD3 Renders T Cell Clones Hypore-
sponsive. Although insufficient for induction of T cell
proliferation or cytokine production, the anti-CD3–IgG3
Figure 1. Non-FcR–binding
anti-CD3 induces proliferation
only in the presence of cross-
linking anti-Ig antibody. Whole
spleen (top) or pGL10 clone cells
(bottom) were cultured with an
anti-CD3–IgG3 chimeric anti-
body and a secondary rabbit anti–
mouse IgG3 Ab mAb for 48 h.
Results are expressed as the
mean of triplicate determinations
and are representative of four in-
dependent experiments.
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mAb may deliver at least a partial signal, which alters T cell
function. Therefore, the effects of anti-CD3–IgG3 on the
functional responses of naive cells and Th1 clones were ex-
amined. pGL10 T cells or DO11.10 lymph node cells were
cultured in the presence of splenic accessory cells (to com-
pensate for the presence of non-T cells in the naive popula-
tion) and nonmitogenic anti-CD3–IgG3. Previous studies
have shown that treatment of T cells with anti-CD3–IgG3
resulted in downmodulation of TCR expression within 24 h
(7). Therefore, after 24 h, the cells were washed, and recul-
tured for 3 d to allow reexpression of the TCR (data not
shown). As seen in Fig. 2 A, upon restimulation with the
mitogenic 145-2C11 mAb plus splenic APCs, thymidine in-
corporation by anti-CD3–IgG3-treated pGL10 was mark-
edly reduced as compared with pGL10 cultured with media
alone. In contrast, the functional responses of murine lymph
node T cells were not affected by culture with anti-CD3–
IgG3. The clonal unresponsiveness did not merely reflect
decreased viability, because anti-CD3–IgG3-treated clones
proliferated in the presence of exogenously added IL-2 (data
not shown). The effect of anti-CD3–IgG3 was not specific
to the pGL10 clone, because the nonmitogenic anti-CD3
rendered the PCC-specific clone, AE.7, hyporesponsive
as well (Fig. 2 B). To determine whether the reduced pro-
liferation of anti-CD3–IgG3-treated T cell clones corre-
lated with IL-2 production, pGL10 clones were cultured
with or without anti-CD3–IgG3 for 24 h, rested, and then
restimulated with immobilized anti-CD3 plus anti-CD28
(PV-1), conditions known to induce readily detectable IL-2
production (Fig. 2 C). Anti-CD3–IgG3-treated clones se-
creted significantly less IL-2 than the media-treated control
cells. These data indicated that exposure to soluble, non-
cross-linked anti-CD3 selectively reduces the responsive-
ness of Th1 clones as compared with naive cells.
To examine whether the presence of CsA or CD28 co-
stimulation would affect the nonmitogenic anti-CD3-induced
unresponsiveness, pGL10 T cells were cultured with non-
mitogenic anti-CD3 alone, or nonmitogenic anti-CD3 in
the presence of CsA, or splenic APCs and anti-CD28 (Fig.
2 D). CsA partially blocked the induction of unresponsive-
ness by nonmitogenic anti-CD3, suggesting that this pro-
cess may depend upon a calcium signal. In contrast, addition
Figure 2. T cell clones, but not lymph node T cells, are hyporesponsive after exposure to nonmitogenic anti-CD3. (A) DO 11.10 lymph node cells or
pGL10 cells were incubated with either media alone or anti-CD3–IgG3 in the presence of irradiated T-depleted spleen cells for 24 h, washed, and rested
for 72 h. The T cells were restimulated with mitogenic anti-CD3 (145-2C11) and fresh APC. (B) AE.7 clone cells were incubated with or without non-
mitogenic anti-CD3, washed, and rested as above, and restimulated with the antigen PCC plus fresh APC. (C) pGL10 cells were incubated with or without
nonmitogenic anti-CD3. After the 72-h rest, the pGL10 were restimulated with immobilized anti-CD3 plus anti-CD28. Culture supernatants were ana-
lyzed by IL-2 ELISA. (D) pGL10 cells were incubated with nonmitogenic anti-CD3 in the presence of cyclosporine A, splenic APC, and anti-CD28 as in-
dicated. 72 h after the primary culture, cells were restimulated with OVA antigen and APC. A, C, and D are representative of two separate experiments,
and B is representative of four experiments.
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of anti-CD28 mAb in the primary culture failed to restore
secondary responses.
Nonmitogenic Anti-CD3 Delivers a Partial TCR Signal.
The functional consequences of culture with nonmitogenic
anti-CD3 support the hypothesis that anti-CD3–IgG3 de-
livers a signal. Therefore, experiments were performed to
determine the nature of the TCR signal triggered by non-
mitogenic anti-CD3. Upon ligation of the TCR, one of
the earliest events to occur is the tyrosine phosphorylation
of components of the TCR complex (z and CD3e, CD3d,
and CD3g) (8). Phosphorylation of these chains allows sub-
sequent association and phosphorylation of a variety of
other proteins, including the protein tyrosine kinase, ZAP-
70 (9). In the present study, the ability of nonmitogenic
anti-CD3 to trigger these crucial proximal events in T cell
clones was examined. T cells were stimulated with the
anti-CD3–IgG3 mAb in the presence or absence of a sec-
ondary Ig cross-linker. The TCR complex was immuno-
precipitated with anti-z and analyzed for tyrosine phosphor-
ylation (Fig. 3 A). Stimulating T cells with anti-CD3 under
cross-linking conditions induced both 21- and 23-kD forms
of phosphorylated z (p21 and p23) as well as phosphoryla-
tion of CD3e. The phosphorylated band below p21 (z18
kD) most likely represents another isoform of phosphory-
lated z (21). In contrast, the noncross-linked anti-CD3–
IgG3 mAb induced similar levels of phosphorylated CD3e
and p21 z, but significantly less p23 z. Quantitation of the
p21 and p23 bands by densitometry in multiple T cell
clone experiments (n 5 4) revealed a consistent correlation
between the degree of anti-CD3 cross-linking and the
p23/p21 ratio; conditions that promote cross-linking in-
creased the relative level of p23 expression (Fig. 3 D).
Examination of the phosphoproteins that coprecipitated
with the z chain in darker exposures or greater cell number
revealed further differences between anti-Ig cross-linked
and noncross-linked conditions (Fig. 3 B). Unlike the cross-
linked anti-CD3 stimulation, several of these phosphopro-
teins (bands between 30 and 46 kD as well as at 70 and 76 kD)
were missing or reduced in the anti-z precipitations from
T cells stimulated with the noncross-linked anti-CD3 mAb.
The proximal signals triggered by nonmitogenic anti-CD3
in lymph node T cells were similar to those induced in
clones in that (a) nonmitogenic anti-CD3 induces phos-
phorylation of TCR chains and (b) in the absence of cross-
linking, several TCR-associated phosphotyrosine contain-
ing proteins are missing or reduced in intensity (Fig. 3 C).
Thus, in both T cell clones and naive T cells, the anti-
CD3–IgG3-induced TCR activation complex (with asso-
Figure 3. Partial tyrosine phosphorylation of TCR components by nonmitogenic anti-
CD3. (A) 107 AE.7 cells or 2 3 107 lymph node cells (C) were stimulated for 2.5 min with
PBS (lane 1), goat anti–IgG3 antisera (lane 2), anti-CD3–IgG3 (lane 3), or anti-CD3–IgG3
plus goat anti–IgG3 (lane 4). Anti-z precipitations were resolved by electropheresis on a 12%
gel and analyzed by Western blotting with anti-phosphotyrosine. (B) pGL10 cells were stim-
ulated for 5 min with PBS, anti-CD3–IgG3, or anti-CD3–IgG3 plus rabbit anti–IgG3 anti-
sera. Lysates were resolved and analyzed as in A. (D) Densitometry was performed on results
from four independent experiments to quantitate the relative amounts of p21- and p23-phos-
phorylated z. In each experiment, the p23/p21 ratios for cross-linked anti-CD3 (hatched bars)
and noncross-linked anti-CD3 (open bars) are represented.
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ciated signaling molecules) contained fewer tyrosine phos-
phorylated molecules than a mitogenically stimulated TCR
complex. These results suggest that although nonmitogenic
anti-CD3 induces some tyrosine phosphorylation of z and
the CD3 chains, it is deficient in triggering other proximal
signaling events.
Previous studies have shown that the 70-kD band ob-
served in anti-z precipitates represents the TCR-associated
tyrosine kinase, ZAP-70 (22). The reduced intensity of this
band in the immunoprecipitates from nonmitogenic anti-
CD3–treated cells could either represent a failure of ZAP-
70 association or deficient phosphorylation. To address this
issue, T cells were stimulated with cross-linked or non-
cross-linked anti-CD3, and the lysates were immunopre-
cipitated with anti-z. The Western blot was probed with
an anti-ZAP-70 antisera. As seen in Fig. 4, the noncross-
linked anti-CD3–IgG3 induced similar levels of ZAP-70
recruitment to the TCR complex; yet as confirmed by re-
probing the blot with anti-phosphotyrosine, the proportion
of ZAP-70 that was tyrosine phosphorylated was signifi-
cantly reduced. Thus, in the absence of CD3 cross-linking,
ZAP-70 associates with the TCR–CD3 complex, but it is
not efficiently phosphorylated.
Defects in Downstream Events in the Absence of TCR–CD3
Cross-linking. The differences in proximal signal transduc-
tion observed in the absence of cross-linking were likely to
be reflected in critical downstream biochemical events,
such as the tyrosine phosphorylation (and thus activation
of) PLCg-1. To examine this event, pGL10 were stimu-
lated with anti-CD3–IgG3 in the presence or absence of
cross-linker (Fig. 5 A). The dramatic increase in PLCg-1
phosphorylation observed in the presence of a secondary
cross-linking Ab was not observed following anti-CD3–
IgG3 stimulation alone. Similarly, cross-linking with anti-
IgG enhanced PLCg-1 tyrosine phosphorylation induced
by the nonmitogenic anti-CD3 in naive cells (Fig. 5 B).
Because anti-CD3–IgG3 was unable to induce signifi-
cant PLCg-1 phosphorylation, it was anticipated that one
of the events that depends upon PLCg-1 activation, Ca21
mobilization, would likewise be impaired. T cell clones
were loaded with the calcium-sensitive dye indo-1 and then
analyzed by FACSÒ  for calcium flux. A calcium flux was
not detected when the cells were stimulated with the anti-
CD3–IgG3 alone, even after 5 min. However, in T cells
incubated with anti-CD3–IgG3 followed by the addition
of a secondary cross-linker, a characteristic calcium flux was
observed within 1 min (Fig. 5 C). Anti-IgG Abs in the ab-
sence of anti-CD3 did not result in a calcium flux (data not
shown). These results demonstrate that the downstream
signaling events of PLCg-1 activation and the ensuing
Ca21 flux are dependent upon extensive cross-linking of
the TCR–CD3 by anti-CD3 mAbs.
Aggregation of the TCR complex has been shown to
correlate with T cell activation; Kupfer et al. (23) demon-
strated that when T cells encounter antigen–MHC on
APCs, the TCR redistributes on the cell surface to form an
aggregated activation cap. This redistribution is a signaling-
dependent process most likely involving reorganization of
the cytoskeleton (24, 25). To test whether the addition of a
cross-linking Ab to anti-CD3 results in an aggregated TCR
cap, confocal microscopy was performed on pGL10 and
purified DO11.10 T cells incubated with anti-CD3 (2C11–
FITC) under cross-linking versus noncross-linking condi-
tions (Fig. 6). In the presence of cross-linking Ab, anti-
Figure 4. Stimulation with non-
cross-linked anti-CD3 is sufficient
for TCR association, but not phos-
phorylation of ZAP-70. 2 3 107
pGL10 T cells were stimulated with
PBS, goat anti–IgG3 alone, anti-
CD3–IgG3, or anti-CD3–IgG3 plus
anti-IgG, for 2.5 min at 378C, lysed,
and immunoprecipitated with anti-z.
Blots were probed with anti-ZAP-
70 (bottom), and then stripped and
reprobed with anti-phosphotyrosine
(top).
Figure 5. Impaired PLCg-1 activation and Ca21 flux in the absence of
anti-CD3 cross-linking. (A) 2 3 107 pGL10 cells were stimulated for 5
min at 378C as indicated. Samples were precipitated with anti-PLCg-1,
and then resolved on an 8% gel. The Western blot was probed with anti-
phosphotyrosine (top), stripped, and then reprobed with anti-PLCg-1
(bottom). (B) 4 3 107 lymph node cells were stimulated for 5 min with PBS,
anti-CD3–IgG3, or anti-CD3–IgG3 plus goat anti–IgG3 and analyzed as
in A. Densitometry performed on this experiment showed a fourfold in-
crease in PLCg-1 phosphorylation (with compensation for protein amount)
upon anti-CD3 cross-linking. (C) T cell clones were loaded with the cal-
cium-sensitive dye indo-1, stimulated with anti-CD3–IgG3 (left), or anti-
CD3–IgG3 followed by rabbit anti–IgG3 (right). Cells were analyzed on a
FACStar Plus Ò  for calcium flux. The rise in relative intracellular calcium
concentration is indicated by an increase in the 405/495 nm emission ra-
tio. (A–C) Data is representative of two separate experiments.
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CD3 stimulation induces aggregation of the TCR into a
cap on one side of the cell. However, in the absence of
cross-linker, the anti-CD3 remained diffusely distributed
on the cell surface. Thus, the signal delivered by nonmito-
genic anti-CD3 appeared insufficient for the redistribution
of TCRs into an aggregated cap.
Recruitment of CD4–lck into the Complex Reconstitutes
Complete Proximal Signal Transduction and Mitogenicity. The
inability of nonmitogenic anti-CD3 to trigger specific
downstream events and proliferation most likely stems from
the defective proximal events observed involving z and
ZAP- 70. Previous studies have suggested that the src fam-
ily kinase, lck, plays a crucial role in the phosphorylation of
z, which subsequently allows association and phosphoryla-
tion of ZAP-70 (26, 27). Thus, it was possible that the dif-
ferences in z and ZAP-70 phosphorylation seen upon the
addition of cross-linker to anti-CD3 may have reflected in-
creased lck activation or enhanced recruitment to the TCR.
Initial experiments examining lck activation by monitoring
lck tyrosine phosphorylation revealed no differences be-
tween cross-linking and noncross-linking conditions. It is
clear that CD4 associates with lck and can interact with the
TCR complex inducibly upon TCR ligation of antigen–
MHC. Thus, artificially bringing CD4–lck into the TCR
complex might reconstitute a mitogenic anti-CD3 stimu-
lus, even in the absence of a secondary cross-linking Ab.
To test this hypothesis, we took advantage of a bispecific
anti-CD3 3 anti-CD4 reagent prepared by a molecular ap-
proach to insure the presence of monovalent arms specific
for CD3 and CD4 (as described in Materials and Methods).
T cells were incubated with anti-CD3–Fos homodimer or
the anti-CD3 3 anti-CD4 bispecific F(ab)92, lysed, and the
TCR–CD3 complex was then immunoprecipitated and
analyzed. The bispecific construct induced significant p23
z, ZAP-70 phosphorylation, as well as association of the
phosphoproteins between 30–46 kD (Fig. 7 A), even in the
absence of a secondary cross-linking antibody. In contrast,
the overall pattern induced by anti-CD3–Fos resembled
the results seen in T cells stimulated with the anti-CD3–
IgG3 mAb: specifically, a reduced association of phospho-
proteins and barely detectable ZAP-70 phosphorylation. In
the lysates of T cells stimulated with the bispecific anti-
CD3 3 anti-CD4 construct, a large tyrosine-phosphorylated
protein was observed that migrated just above the heavy
chain. This phosphoprotein is likely to be p56 lck based on
protein size. This band never appeared in the cross-linked
anti-CD3 studies. One possible explanation for this differ-
ence is that in the absence of CD4 coaggregation, lck may
dissociate from the TCR complex after lck phosphorylates
its substrates. Whereas under stimulation conditions using
the bispecific antibody, lck remains in the complex longer
due to stable association with coaggregated CD4.
The biochemical results suggested that the anti-CD3 3
anti-CD4 bispecific antibody delivered a competent acti-
vating signal to the T cells. In fact, T cell clones or fresh
murine T cells cultured in the presence of anti-CD3 3
anti-CD4 heterodimer proliferated, whereas T cells cul-
tured with the anti-CD3–Fos homodimer did not (Fig. 7
B). Thus, enhanced association of lck with the TCR com-
plex reconstituted both early signaling events and a mitoge-
nic stimulus in the absence of further Ab cross-linking.
Discussion
In this study, we have shown that bivalent anti-CD3
delivers a partial TCR signal that renders Th1 clones hypo-
responsive. This signal consists of phosphorylation of sev-
eral components of the TCR complex, (bands representing
CD3e, CD3d), ZAP-70 association, and partial phosphory-
lation of TCR z; in the absence of cross-linking, there is a
relatively greater induction of the phosphorylated p21 z as
compared with the p23 z band species evident in T cell
clones. Presently, it is unclear what the p21 and p23 forms
of z represent. p21 induction appears to be sufficient for
Figure 6. In the presence of a
secondary cross-linker, anti-CD3
induces formation of an aggre-
gated TCR cap. pGL10 T cells
(left two columns) or purified DO
11.10 T cells (right two columns)
were stimulated with anti-CD3–
FITC at 378C in the absence (left
for each T cell type) or presence
(right for each cell type) of goat
anti–hamster cross-linking anti-
sera. Cells were fixed at 0 min
(top row) and 5 min (bottom row)
after addition of cross-linker, and
analyzed by confocal micros-
copy.
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association of the ZAP-70 kinase with the TCR complex,
whereas p23 induction and ZAP-70 phosphorylation ap-
pear to be interrelated events. Indeed, the low level of
ZAP-70 phosphorylation observed in the noncross-linked
situation correlates with the small amount of p23 z that is
generated. In a recent study, Weist et al. (28) proposed that
the p23 form of z observed in thymocytes upon in vitro
stimulation depends on greater TCR aggregation. Our find-
ings are consistent with this hypothesis. Higher orders of
TCR aggregation also appear to be required for recruit-
ment of other phosphotyrosine containing molecules to the
TCR–CD3 complex in both T cell clones and bulk naive
cells. If any of these tyrosine-phosphorylated molecules con-
tain SH2 domains, they may require the fully phosphory-
lated p23 form of z for association. Alternatively, the p23
form may be required for docking of a kinase that phos-
phorylates these associated molecules.
The observation that noncross-linked anti-CD3 induces
less ZAP-70 phosphorylation and p23 phospho-z bears a
striking resemblance to the findings in the altered peptide
ligand studies (10, 13). The relative contribution of affinity
for MHC or TCR (and thus occupancy) versus TCR ag-
gregation has been unclear in these systems. Recently, Ly-
ons et al. (29) showed a correlation between antagonist ac-
tivity of certain altered peptide ligands and a higher TCR
dissociation rate. However, this finding does not exclude a
role for aggregation in that a shorter dwell time of the
TCR may fail to induce the oligomerization required for a
fully activating stimulus. In the present study, the issue of
affinity has been addressed; the same primary antibody was
used in both cross-linked and noncross-linked situations;
thus, intrinsic affinity for TCR was held constant. Because
similar signaling deficits were found in noncross-linked
anti-CD3 and altered peptide ligand stimulations, it is pos-
sible that the altered peptide ligands may induce their char-
acteristic partial signals because of insufficient TCR aggre-
gation.
There are several ways in which the localization of mul-
tiple TCR complexes within a large aggregate could en-
hance signaling. In the kinetic proofreading model pro-
posed by McKeithan (30), TCR signal transduction was
modeled as a reversible multistep pathway containing se-
quential phosphorylation events. In this paradigm, aggrega-
tion of TCRs might enhance propagation of the signal by
favoring phosphorylation over dephosphorylation. On a
more mechanistic level, aggregation may aid in recruiting
key signaling molecules; recruitment of molecules may be
further stabilized if there are multiple potential contact points
(catalytic sites, SH2 domains, or other recognition motifs)
between components of the TCR complex that are in close
proximity. For example, if lck binds one phosphorylated
ZAP-70 through its SH2 domain, the lck would be in a
prime position to phosphorylate a neighboring ZAP-70
molecule in the TCR aggregate. In the noncross-linked
situation, lck might migrate away before phosphorylating
more ZAP-70 molecules. Thus, aggregated TCR signal
transduction may result in amplification of these signals, be-
cause one kinase may act on multiple substrates. This ca-
pacity for amplification would mean that proximal differ-
ences should become magnified as the signal is propagated.
As seen in the present study, a relative reduction in ZAP-
70 phosphorylation leads to a more dramatic deficiency in
PLCg-1 phosphorylation and Ca21 flux.
The redistribution of TCR complexes to one pole, within
minutes upon addition of secondary cross-linker to anti-
CD3, is likely to reflect changes in the underlying cytoskel-
eton. Others have shown that TCR engagement can lead
to redistribution of cytoskeletal elements such as talin, vin-
culin, and actin (9, 24). The cross-linking Ab might be
providing sufficient TCR aggregation to trigger a threshold
signal for cytoskeletal mobilization. Studies by Valetutti et al.
(25) have suggested that the cytoskeleton also plays an ac-
tive role in sustaining a TCR signal, because the addition
of agents which disrupt the actin cytoskeleton (e.g., Cyto-
cholasin D) can block the rise in intracellular Ca21. The
cross-linked anti-CD3 system may be useful for dissecting
the role of the cytoskeleton in proximal signaling events.
Our experiments suggest that efficient recruitment of lck
may be the pivotal event accomplished by aggregation. Lck
has been shown to be important for proximal signaling in
that absence of lck almost completely abrogates tyrosine
phosphorylation events (9, 31). It is well established that
coaggregating anti-CD3 and anti-CD4 antibodies or using
anti-CD3/anti-CD4 heteroconjugate mAbs can result in
enhanced tyrosine phosphorylation and calcium mobiliza-
tion (32). Recently, it was shown that in circumstances in
which lck is limiting, as in double-positive thymocytes,
Figure 7. Stimulation with anti-CD3 3 anti-CD4 heterodimer results
in increased phosphorylation of proteins associated with the TCR com-
plex and reconstitutes a mitogenic stimulus. (A) 107 pGL10 T cells were
stimulated with the anti-CD3–Fos F(ab)92, or the bispecific F(ab)92 (anti-
CD3 3 anti-CD4) for 5 min at 378C. Samples were precipitated with
anti-z, and blots were probed with anti-phosphotyrosine as in Fig. 2 A.
(B) Whole spleen (top) or pGL10 T cells (bottom) were cultured with serial
log dilutions of anti-CD3–Fos homodimer (open diamonds) or bispecific
anti-CD3 3 anti-CD4 (closed diamonds) for 48 h. Data is representative of
two (A) and three (B) separate experiments.
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ZAP-70 phosphorylation requires coaggregation of TCR
and CD4 (28). Furthermore, blockading CD4 (and pre-
sumably its associated lck molecules) with anti-CD4 mAbs
can convert a partial agonist signal into an antagonist signal
with its associated characteristic signaling deficits (33). Thus,
impaired CD4 recruitment has been proposed as a mecha-
nism for altered peptide/antagonist peptide signaling. The
pivotal nature of lck recruitment is underscored by our
finding that secondary antibody induced aggregation can be
dispensed with, if lck is recruited by bringing CD4 into the
complex artificially. Even in the absence of exogenous
cross-linking, stimulation with a bivalent anti-CD3 3 anti-
CD4 reagent reconstituted both the early signaling events
of ZAP-70 phosphorylation and association of other phos-
phorylated proteins with the complex. In turn, these early
events lead ultimately to a mitogenic stimulus.
The partial signals delivered by nonmitogenic anti-CD3
correlated with the induction of functional anergy as de-
fined by an inability to proliferate due to poor IL-2 pro-
duction. The striking similarity between the signals deliv-
ered by altered peptide ligands and nonmitogenic anti-CD3
are perhaps indicative of a common mechanism of anergy
induction. How these partial signals translate into an off
signal that shuts down T cell clonal responsiveness has yet
to be determined. In the classical model of anergy, involv-
ing a complete signal one (through the TCR) in the ab-
sence of signal two (costimulation), induction of unrespon-
siveness depends upon a successful calcium signal that can
be blocked by CsA (34, 35). Similarly, CsA has been
shown to block anergy induction by altered peptide ligands
(12). In fact, an altered peptide ligand triggered calcium sig-
nal has been recently demonstrated using an exquisitely
sensitive system (36). The ability of CsA to block nonmito-
genic anti-CD3–induced functional anergy suggests that a
calcium signal may be important in this process. It is possible
that the lack of detectable calcium flux by nonmitogenic
anti-CD3 reflects insufficient sensitivity. In contrast with the
classical models of anergy, the presence of competent APC
or anti-CD28 antibodies did not rescue T cell clones from
nonmitogenic anti-CD3–induced unresponsiveness.
An unresolved observation was the finding that culture
with the nonmitogenic anti-CD3 suppresses IL-2 produc-
tion in clones, but it did not appear to impair significantly
the responsiveness of bulk T cells. Our results suggest simi-
lar defects in signaling between naive cells and clones in
terms of ZAP-70 phosphorylation and TCR–CD3 com-
plex–associated phosphorylated molecules, as well as the
downstream events of PLCg-1 phosphorylation and TCR
capping. It is possible that naive cells and clones differ in
the way they respond to nonmitogenic anti-CD3 mAbs,
either in the triggering of other biochemical signals, or the
integration of downstream nuclear signals.
The mitogenic forms of anti-CD3 currently in use se-
verely suppress global T cell responses. This study suggests
that nonmitogenic anti-CD3 may selectively induce unre-
sponsiveness in activated T cell subsets. These findings bear
promising implications for transplant therapy in that it would
be beneficial to be able to suppress the alloreactive T cells that
mediate graft rejection, while maintaining the responsive-
ness of other T cells. Further investigation into the mecha-
nisms by which nonmitogenic anti-CD3 modulates T cell
responses should shed some light on the applicability of this
potential therapeutic to transplantation.
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